Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regorafenib + trifluridine + tipiracil
- Development stage
- Unknown
- Lead developer
- TRF Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
regorafenib + TAS-102 is a combination therapy being developed by TRF Pharma (Therapeutic Repurposing Foundation) for the treatment of sickle cell disease (SCD). This therapeutic strategy involves the repurposing of two established oncology treatments: regorafenib (TRF-1101), a multi-kinase inhibitor, and TAS-102 (TRF-1201), which consists of the nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. The combination is designed to induce the production of fetal hemoglobin (HbF), which prevents the polymerization of sickle hemoglobin (HbS) and the subsequent sickling of red blood cells. By increasing HbF levels and improving microvascular blood flow, the therapy aims to reduce vaso-occlusive crises and associated pain. TRF-1101 is currently being evaluated in Phase 1/2 clinical trials for SCD, while the combination with TAS-102 is part of a broader program to optimize HbF induction through synergistic mechanisms.
- Brand names
- StivargaLonsurf
- Other names
- regorafenib + TAS-102
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TEK (Tie2)PDGFRB (Platelet-derived growth factor receptor beta)TYMP (Thymidine phosphorylase)RAF1 (c-Raf-1 (Y340D/Y341D))DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on regorafenib + trifluridine + tipiracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regorafenib + trifluridine + tipiracil.